Jack A.  Khattar net worth and biography

Jack Khattar Biography and Net Worth

President and Chief Executive Officer, Director of Supernus Pharmaceuticals

Jack A. Khattar is the founder of our company and has served as our President, Chief Executive Officer (CEO), and Director since 2005. From 1999 to 2005, Mr. Khattar served in various positions as a Board member, President, and CEO of Shire Laboratories, Inc., the drug delivery subsidiary of Shire plc. From 1999 to 2004, he also served as a member of Shire plc’s Executive Committee. Prior to that, Khattar served as an Executive Officer and the Chairman of the Management Committee at CIMA Labs Inc., a drug delivery company, where he was also responsible for business development, corporate alliances, and strategic planning. Prior to joining CIMA in 1995, Mr. Khattar held several marketing and business development positions at Merck & Co., Novartis, Playtex, and Kodak in various locations, including the United States, Europe, and the Middle East. Mr. Khattar served on the Board of Rockville Economic Development Inc. from 2003 until 2013. He currently serves on the Board of Directors of Prevacus, Inc., a privately held development stage biotechnology company, and is also Chairman of the Board of scPharmaceuticals, a publicly traded biotechnology company. Mr. Khattar earned his degrees in Marketing with a BBA from American University of Beirut and an MBA from the Wharton School of the University of Pennsylvania.

What is Jack A. Khattar's net worth?

The estimated net worth of Jack A. Khattar is at least $29.09 million as of November 7th, 2024. Mr. Khattar owns 926,172 shares of Supernus Pharmaceuticals stock worth more than $29,090,136 as of March 14th. This net worth estimate does not reflect any other assets that Mr. Khattar may own. Additionally, Mr. Khattar receives an annual salary of $1,630,000.00 as President and Chief Executive Officer, Director at Supernus Pharmaceuticals. Learn More about Jack A. Khattar's net worth.

How old is Jack A. Khattar?

Mr. Khattar is currently 63 years old. There are 5 older executives and no younger executives at Supernus Pharmaceuticals. Learn More on Jack A. Khattar's age.

What is Jack A. Khattar's salary?

As the President and Chief Executive Officer, Director of Supernus Pharmaceuticals, Inc., Mr. Khattar earns $1,630,000.00 per year. Learn More on Jack A. Khattar's salary.

How do I contact Jack A. Khattar?

The corporate mailing address for Mr. Khattar and other Supernus Pharmaceuticals executives is 1550 E GUDE DR, ROCKVILLE MD, 20850. Supernus Pharmaceuticals can also be reached via phone at (301) 838-2500 and via email at gpatrick@supernus.com. Learn More on Jack A. Khattar's contact information.

Has Jack A. Khattar been buying or selling shares of Supernus Pharmaceuticals?

Jack A. Khattar has not been actively trading shares of Supernus Pharmaceuticals during the past quarter. Most recently, Jack A. Khattar sold 125,000 shares of the business's stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $36.68, for a transaction totalling $4,585,000.00. Following the completion of the sale, the chief executive officer now directly owns 926,172 shares of the company's stock, valued at $33,971,988.96. Learn More on Jack A. Khattar's trading history.

Who are Supernus Pharmaceuticals' active insiders?

Supernus Pharmaceuticals' insider roster includes Padmanabh Bhatt (Senior Vice President, Chief Scientific Officer, Intellectual Property), Georges Gemayel (Director), Frederick Hudson (Director), Jack Khattar (President and Chief Executive Officer, Director), Frank Mottola (SVP, GMP Operations, IT and Regulatory Affairs), and Jonathan Rubin (Senior Vice President, Chief Medical Officer, Research & Development). Learn More on Supernus Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Supernus Pharmaceuticals?

In the last twelve months, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 192,172 shares worth more than $7,048,693.06. The most recent insider tranaction occured on February, 21st when SVP Jonathan Rubin sold 927 shares worth more than $36,292.05. Insiders at Supernus Pharmaceuticals own 9.3% of the company. Learn More about insider trades at Supernus Pharmaceuticals.

Information on this page was last updated on 2/21/2025.

Jack A. Khattar Insider Trading History at Supernus Pharmaceuticals

See Full Table

Jack A. Khattar Buying and Selling Activity at Supernus Pharmaceuticals

This chart shows Jack A Khattar's buying and selling at Supernus Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table
2022202320242025$0bought$0soldQ1Q2Q3Q4Q1Q2Q3Q4Q1Q2Q3Q4Q1-$4M-$2M$0$2M$4MTotal Insider BuyingTotal Insider Selling

Supernus Pharmaceuticals Company Overview

Supernus Pharmaceuticals logo
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $31.41
Low: $30.30
High: $30.30

50 Day Range

MA: $36.44
Low: $31.38
High: $40.00

2 Week Range

Now: $31.41
Low: $25.53
High: $40.28

Volume

337 shs

Average Volume

553,427 shs

Market Capitalization

$1.75 billion

P/E Ratio

29.42

Dividend Yield

N/A

Beta

0.83